BioTuesdays

Category - Markets

Acasti Pharma
Markets

Mackie puts Acasti Pharma under review; removes PT

Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...

January 13, 2020
Markets

Roth starts Millendo Therapeutics at buy; PT $35

Roth Capital Partners launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $35 price target. The stock closed at $7.63 on Jan. 9. Millendo is a clinical-stage company focusing on the...

January 10, 2020
Markets

SVB Leerink starts Organogenesis at OP; PT $9

SVC Leerink initiated coverage of Organogenesis (NASDAQ:ORGO) with an “outperform” rating and $9 price target. The stock closed at $4.84 on Jan. 9. Organogenesis is a regenerative medicine company with a portfolio of...

January 10, 2020
Profound Medical
Markets

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

January 10, 2020
Cassava Sciences
Markets

Maxim ups Cassava Sciences PT to $12 from $3

Maxim Group raised its price target for Cassava Sciences (NASDAQ:SAVA) to $12 from $3, citing the recent rise in the company’s share price. The stock closed at $7.93 on Jan. 9. “Cassava’s shares have risen significantly...

January 10, 2020
iRhythm Technologies
Markets

WB starts iRhythm Technologies at OP

William Blair launched coverage of iRhythm Technologies (NASDAQ:IRTC) with an “outperform” rating, calling the company’s digital health platform “market disrupting.” The stock closed at $71.76, up $1.12, on Jan. 9...

January 10, 2020
Xenon Pharma
Markets

WB starts Xenon Pharma at OP; estimated fair value $27

William Blair initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with an “outperform” rating and estimated fair value of $27. The stock closed at $13.49 on Jan. 7. Xenon is focused on the development of selective...

January 8, 2020
X4 Pharma
Markets

HCW starts X4 Pharma at buy; PT $22

H.C. Wainwright launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $22 price target. The stock closed at $10.39 on Jan. 6. The company’s lead product candidate, mavorixafor, is a potential...

January 7, 2020
Markets

Roth starts Crinetics Pharma at buy; PT $37

Roth Capital Partners launched coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a “buy” rating and $37 price target. The stock closed at $21.91 on Dec. 20. Crinetics is a clinical-stage pharmaceutical company...

December 23, 2019

Subscribe

Sign up to our weekly BioTuesdays newsletter.